KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Free Cash Flow (2016 - 2025)

NovoCure's Free Cash Flow history spans 12 years, with the latest figure at -$22.9 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 84.78% year-over-year to -$22.9 million; the TTM value through Dec 2025 reached -$75.7 million, down 9.32%, while the annual FY2025 figure was -$75.7 million, 9.32% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$22.9 million at NovoCure, down from $14.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $23.6 million in Q2 2021 and bottomed at -$46.3 million in Q1 2025.
  • The 5-year median for Free Cash Flow is -$11.3 million (2022), against an average of -$8.9 million.
  • The largest annual shift saw Free Cash Flow plummeted 7898.46% in 2022 before it surged 4959.61% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $130000.0 in 2021, then tumbled by 7898.46% to -$10.1 million in 2022, then crashed by 110.88% to -$21.4 million in 2023, then skyrocketed by 42.03% to -$12.4 million in 2024, then plummeted by 84.78% to -$22.9 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Free Cash Flow are -$22.9 million (Q4 2025), $14.9 million (Q3 2025), and -$21.4 million (Q2 2025).